Weekly Investment Analysts’ Ratings Updates for Pfizer (PFE)

Several analysts have recently updated their ratings and price targets for Pfizer (NYSE: PFE):

• 10/17/2024 – Pfizer is now covered by analysts at Sanford C. Bernstein. They set a “market perform” rating and a $32.00 price target on the stock.
• 10/9/2024 – Pfizer was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/3/2024 – Pfizer had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
• 10/1/2024 – Pfizer was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/16/2024 – Pfizer had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
• 9/9/2024 – Pfizer had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.

Pfizer Stock Down 1.0 %

Shares of Pfizer stock traded down $0.29 during trading on Monday, reaching $28.93. 23,373,940 shares of the company traded hands, compared to its average volume of 37,036,055. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a 50 day moving average price of $29.07 and a 200-day moving average price of $28.45. The firm has a market capitalization of $163.93 billion, a PE ratio of -482.17, a P/E/G ratio of 1.02 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.67 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.81%. Pfizer’s payout ratio is -2,800.00%.

Institutional Trading of Pfizer

Several institutional investors have recently made changes to their positions in the company. Telos Capital Management Inc. grew its stake in shares of Pfizer by 1.9% in the 3rd quarter. Telos Capital Management Inc. now owns 21,553 shares of the biopharmaceutical company’s stock worth $624,000 after acquiring an additional 397 shares in the last quarter. Copeland Capital Management LLC bought a new stake in shares of Pfizer in the 3rd quarter worth $144,000. Northwest Investment Counselors LLC bought a new position in Pfizer during the third quarter valued at about $103,000. Livelsberger Financial Advisory bought a new position in Pfizer during the third quarter valued at about $124,000. Finally, Little House Capital LLC grew its position in Pfizer by 16.2% during the third quarter. Little House Capital LLC now owns 40,196 shares of the biopharmaceutical company’s stock valued at $1,163,000 after buying an additional 5,593 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.